口服罗沙司他与重组人促红细胞生成素治疗慢性维持性透析合并肾性贫血患者的效果比较  

Comparison on the curative effect of oral Roxadustat and recombinant human erythropoietin in patients with renal anemia undergoing chronic maintenance hemodialysis

作　　者：黄鹤宁 魏锋[2] HUANG Hening;WEI Feng(Department of Nephrology,Fuzhou Second Hospital,Fujian Province,Fuzhou 350007,China;Department of Neurology,Fuzhou Second Hospital,Fujian Province,Fuzhou 350007,China)

机构地区：[1]福州市第二医院肾内科,福建福州350007 [2]福州市第二医院神经内科,福建福州350007

出　　处：《中国当代医药》2023年第16期100-103,共4页China Modern Medicine

基　　金：福建省福州市科技计划项目(2018-S-101-2,2019D006)。

摘　　要：目的比较分析口服罗沙司他与重组人促红细胞生成素(rhEPO)治疗慢性维持性透析(MHD)合并肾性贫血(RA)患者的效果。方法选取2021年9月至2022年6月福州市第二医院收治的72例MHD合并RA患者作为研究对象,按照随机数字表法分成对照组(36例)和观察组(36例)。对照组静脉注射rhEPO,观察组口服罗沙司他,均治疗3个月。比较两组患者的疗效、贫血指标[红细胞(RBC)、血红蛋白(Hb)、血细胞比容(HCT)]、铁代谢指标[血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)、运铁蛋白(Tf)]和不良反应发生率的变化。结果观察组治疗后的总有效率高于对照组,差异有统计学意义(P<0.05)。两组患者治疗后RBC、Hb、HCT、SF、TSAT、Tf水平高于本组治疗前,且观察组治疗后的RBC、Hb、HCT、SF、TSAT、Tf水平高于对照组,差异有统计学意义(P<0.05)。观察组治疗后的不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论口服罗沙司他比静注rhEPO治疗MHD合并RA患者的效果更加显著,能够提高患者的RBC、Hb、HCT水平和SF、TSAT、Tf等指标的利用率,进而促进血液循环,维持血液铁代谢平衡,减少不良反应的发生。Objective To compare and analyze the curative effect of oral Roxadustat and recombinant human erythropoietin(rhEPO)in patients with renal anemia(RA)undergoing chronic maintenance hemodialysis(MHD).Methods A total of 72 patients with RA undergoing MHD admitted to Fuzhou Second Hospital from September 2021 to June 2022 were selected as the study subjects.They were divided into control group(36 cases)and observation group(36 cases)according to random number table method.The control group received intravenous injection of rhEPO,while the observation group received oral administration of Roxadustat,both received treatment for 3 months.The efficacy,anemia indicators(red blood cell[RBC],hemoglobin[Hb],hematocrit[HCT]),iron metabolism indicators(serum ferritin[SF],transferrin saturation[TSAT],transferrin[Tf])and changes in the incidence of adverse reactions between the two groups were compared.Results The total effective rate of the observation group after treatment was higher than that of the control group,with statistically significant difference(P<0.05).The levels of RBC,Hb,HCT,SF,TSAT and Tf in the two groups of patients after treatment were higher than those before treatment,and the levels of RBC,Hb,HCT,SF,TSAT and Tf in the observation group after treatment were higher than those in the control group,with statistical significances(P<0.05).The total incidence of adverse reactions after treatment in the observation group was lower than that in the control group,with statistically significant difference(P<0.05).Conclusion Oral Roxadustat is more effective than intravenous injection of rhEPO in treating patients with RA undergoing MHD.It can improve the levels of RBC,Hb,HCT and the utilization rate of SF,TSAT,Tf and other indicators in patients,thereby promoting blood circulation,maintaining blood iron metabolism balance and reducing the occurrence of adverse reactions.

关 键 词：罗沙司他 重组人促红细胞生成素 慢性维持性透析 肾性贫血 比较分析 

分 类 号：R692.5[医药卫生—泌尿科学]